Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-001 with Chemoradiation in Anal Cancer
NCT03386500Phase 2Active, not recruiting
- Sponsor
- University of Nebraska
- Start
- Nov 2017
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of manganese butoxyethyl pyridyl porphyrin in anal squamous cell carcinoma (SCCA), sponsored by University of Nebraska. Started Nov 2017; status: active, not recruiting.
02
Drugs
manganese butoxyethyl pyridyl porphyrin
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT03386500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386500.